Page 265 - 2021_02-Haematologica-web

Letters to the Editor
analyzed data and supervised research; AB, ADS, PTA and MA wrote the paper; all authors reviewed and edited the paper; 5FTRX was developed by Medivir AB, Sweden, which has interests in nucleotide/nucleoside
science to develop pharmaceuticals that meet unmet medical needs.
Acknowledgments: we thank Jill Flewelling (Princess Margaret Cancer Center) for administrative assistance. We would like to thank Andrew Minchinton and Alistair Kyle for the immunofluorescence analyses.
Funding: this work was supported by Medivir AB, the Canadian Institutes of Health Research, the Princess Margaret Cancer Centre Foundation, and the Ministry of Long-Term Health and Planning in the Province of Ontario. ADS holds the Barbara Baker Chair in Leukemia and Related Diseases.
References
1. Döhner H, Estey EH, Amadori S, et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an
international expert panel, on behalf of the European LeukemiaNet.
Blood. 2010;115(3):453-474.
2.Dumontet C, Fabianowska-Majewska K, Mantincic D, et al.
Common resistance mechanisms to deoxynucleoside analogues in variants of the human erythroleukaemic line K562. Br J Haematol. 1999;106(1):78-85.
3. Galmarini CM, Thomas X, Calvo F, et al. Potential mechanisms of resistance to cytarabine in AML patients. Leuk Res. 2002;26(7):621- 629.
4. Hyo Kim L, Sub Cheong H, Koh Y, et al. Cytidine deaminase poly- morphisms and worse treatment response in normal karyotype AML. J Hum Genet. 2015;60(12):749-754.
5. Schroder JK, Kirch C, Seeber S, Schutte J. Structural and functional analysis of the cytidine deaminase gene in patients with acute myeloid leukaemia. Br J Haematol. 1998;103(4):1096-1103.
6. Veuger MJ, Honders MW, Landegent JE, Willemze R, Barge RM. High incidence of alternatively spliced forms of deoxycytidine kinase in patients with resistant acute myeloid leukemia. Blood. 2000;96(4):1517-1524.
7.Murphy JM, Armijo AL, Nomme J, et al. Development of new deoxycytidine kinase inhibitors and noninvasive in vivo evaluation using positron emission tomography. J Med Chem. 2013; 56(17):6696-6708.
haematologica | 2021; 106(2)
579